Published On: Wed, Oct 19th, 2016

New Analyst Ratings On Macrocure Ltd. (MCUR)


Recently stock market analysts have updated their consensus ratings on shares of Macrocure Ltd. (MCUR).

Most recent broker ratings

07/18/2016 – Macrocure Ltd. was downgraded to “underperform” by analysts at Credit Suisse. They now have a USD 1 price target on the stock.

10/28/2015 – Macrocure Ltd. had its “hold” rating reiterated by analysts at Jefferies. They now have a USD 1.5 price target on the stock.

08/20/2015 – Macrocure Ltd. was downgraded to “neutral” by analysts at Nomura. They now have a USD 6 price target on the stock.

08/20/2015 – Macrocure Ltd. was downgraded to “perform” by analysts at Oppenheimer.

08/25/2014 – Credit Agricole began new coverage on Macrocure Ltd. giving the company a “outperform” rating. They now have a USD 15 price target on the stock.

Macrocure Ltd. has a 50 day moving average of 1.57 and a 200 day moving average of 1.35. The stock’s market capitalization is 27.62M, it has a 52-week low of 0.75 and a 52-week high of 4.26.

The share price of the company (MCUR) was up +0.65% during the last trading session, with a high of 1.65 and the volume of Macrocure Ltd. shares traded was 119804.

MacroCure Ltd. is a biotechnology company. The Company is focused on developing, manufacturing and commercializing cell therapy products to address unmet needs for the treatment of chronic wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Its product candidate, CureXcell, is a combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure. CureXcell is in Phase III. Its CureXcell addresses each phase of healing in the impaired wound, including the production of growth factors and other biochemical factors involved in fibroblast activation, cell migration and extracellular matrix production, stimulating the body’s natural healing process. Its delivery method of direct superficial injection into the chronic wound allows the precise delivery of the cells into the defective wound tissue where they can be effective.